Dual‐Targeted Novel Temozolomide Nanocapsules Encapsulating siPKM2 Inhibit Aerobic Glycolysis to Sensitize Glioblastoma to Chemotherapy
Advanced Materials · 2024
DOI: 10.1002/adma.202400502 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2024. Verfasst von Yongkang Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, 221002, China. Hauptthemen laut MEDLINE: Glioblastoma, Temozolomide, Nanocapsules, Glycolysis. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Social Development Project of Jiangsu Department of Science and Technology, Postgraduate Research & Practice Innovation Program of Jiangsu Province.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Chemotherapy of glioblastoma (GBM) has not yielded success due to inefficient blood–brain barrier (BBB) penetration and poor glioma tissue accumulation. Aerobic glycolysis, as the main mode of energy supply for GBM, safeguards the rapid growth of GBM while affecting the efficacy of radiotherapy and chemotherapy. Therefore, to effectively inhibit aerobic glycolysis, increase drug delivery efficiency and sensitivity, a novel temozolomide (TMZ) nanocapsule (ApoE‐MT/siPKM2 NC) is successfully designed and prepared for the combined delivery of pyruvate kinase M2 siRNA (siPKM2) and TMZ. This drug delivery platform uses siPKM2 as the inner core and methacrylate‐TMZ (MT) as the shell component to achieve inhibition of glioma energy metabolism while enhancing the killing effect of TMZ. By modifying apolipoprotein E (ApoE), dual targeting of the BBB and GBM is achieved in a “two birds with one stone” style. The glutathione (GSH) responsive crosslinker containing disulfide bonds ensures “directional blasting” cleavage of the nanocapsules to release MT and siPKM2 in the high GSH environment of glioma cells. In addition, in vivo experiments verify that ApoE‐MT/siPKM2 NC has good targeting ability and prolongs the survival of tumor‐bearing nude mice. In summary, this drug delivery system provides a new strategy for metabolic therapy sensitization chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, 221002, China.
- Department of Neurosurgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China.
- Department of Nephrology, Xuzhou Central Hospital, Xuzhou, 221009, China.
ORCID-Profile: Yongkang Zhang, Rutong Yu
Förderung
- National Natural Science Foundation of China
- Social Development Project of Jiangsu Department of Science and Technology
- Postgraduate Research & Practice Innovation Program of Jiangsu Province
- Xuzhou Key R&D Plan
Zitieren
APA
Zhang, Y., Ma, H., Li, L., Sun, C., Yu, C., Wang, L., Xu, D., Song, X., & Yu, R. (2024). Dual‐Targeted Novel Temozolomide Nanocapsules Encapsulating siPKM2 Inhibit Aerobic Glycolysis to Sensitize Glioblastoma to Chemotherapy. Advanced Materials. https://doi.org/10.1002/adma.202400502
Vancouver
Zhang Y, Ma H, Li L, Sun C, Yu C, Wang L, et al. Dual‐Targeted Novel Temozolomide Nanocapsules Encapsulating siPKM2 Inhibit Aerobic Glycolysis to Sensitize Glioblastoma to Chemotherapy. Advanced Materials. 2024. doi:10.1002/adma.202400502
BibTeX
@article{Zhang2024,
author = {Zhang, Yongkang and Ma, Hongwei and Li, Linsen and Sun, Chen and Yu, Changshui and Wang, Lansheng and Xu, Duo and Song, Xu and Yu, Rutong},
title = {Dual‐Targeted Novel Temozolomide Nanocapsules Encapsulating siPKM2 Inhibit Aerobic Glycolysis to Sensitize Glioblastoma to Chemotherapy},
journal = {Advanced Materials},
year = {2024},
doi = {10.1002/adma.202400502}
}
EUVIMED